Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Liabilities and Shareholders Equity: 2015-2024

Historic Liabilities and Shareholders Equity for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $139.8 million.

  • Seres Therapeutics' Liabilities and Shareholders Equity fell 19.73% to $143.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $591.3 million, marking a year-over-year decrease of 50.74%. This contributed to the annual value of $139.8 million for FY2024, which is 61.01% down from last year.
  • According to the latest figures from FY2024, Seres Therapeutics' Liabilities and Shareholders Equity is $139.8 million, which was down 61.01% from $358.6 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Liabilities and Shareholders Equity ranged from a high of $358.6 million in FY2023 and a low of $139.8 million during FY2024.
  • Over the past 3 years, Seres Therapeutics' median Liabilities and Shareholders Equity value was $348.8 million (recorded in 2022), while the average stood at $282.4 million.
  • In the last 5 years, Seres Therapeutics' Liabilities and Shareholders Equity soared by 158.94% in 2020 and then crashed by 61.01% in 2024.
  • Seres Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $342.9 million in 2020, then increased by 3.48% to $354.9 million in 2021, then dropped by 1.71% to $348.8 million in 2022, then climbed by 2.81% to $358.6 million in 2023, then plummeted by 61.01% to $139.8 million in 2024.